Key clinical point: Timing of pancreatic enzyme replacement therapy (PERT) did not influence abdominal pain among children and adolescents with cystic fibrosis (CF) and pancreatic insufficiency (PI).
Major finding: No significant change was observed in the occurrence, intensity, and duration of abdominal pain with the change of PERT timing from before to after meals and vice versa (all P > .05).
Study details: This randomized, cross-over trial included 30 Danish patients (age 0-17 years) with CF and PI. Patients were randomly assigned to take their usual PERT dose before meals for 4 weeks, followed by after meals for 4 weeks, and vice versa.
Disclosures: This study was funded by grants from the Danish Ronald McDonald Children’s Fund and the Danish Cystic Fibrosis Foundation to M Skov, AMT Raun, and G Brekke. The authors declared no conflict of interests.
Source: Raun AMT et al. Acta Paediatr. 2021 Oct 8. doi: 10.1111/apa.16143.
